

ESMO PRECEPTORSHIP PROGRAMME

LUNG CANCER

New standards of care and future perspectives

Paris, France
15-16 November 2024

CO-CHAIRS: Solange Peters, Switzerland
David Planchard, France

SPEAKERS: Fabrice Barlesi, France
Benjamin Besse, France
Anne-Marie Dingemans, The Netherlands
Patrick Forde, Ireland
Lizza Hendriks, The Netherlands
Keith M. Kerr, United Kingdom
Cécile Le Pechoux, France
Noemi Reguart, Spain
Jordi Remon, France

LEARNING OBJECTIVES

- To learn about best clinical practice in the management of NSCLC in early, locally advanced, and metastatic stages
- To learn about the management of patients with actionable driver alterations and novel targeted agents for advanced NSCLC
- To understand the role of immune checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about the systemic treatment of mesothelioma, SCLC and thymoma

Friday, 15 November 2024

09:00-09:10 10'	Welcome and introduction	Solange Peters, CH David Planchard, FR
09:10-11:15 125'	SESSION 1 Advances in the treatment of early stage NSCLC	Chairs: Lizza Hendriks, NL David Planchard, FR
30'	Introduction of immunotherapy in the perioperative setting	Patrick Forde, IE
5'	Q&A	All
25'	Targeted therapy in the perioperative setting	Jordi Remon, FR
5'	Q&A	All
25'	Immunotherapy as a component of definitive radiochemotherapy for stage III	Cécile Le Pechoux, FR
5'	Q&A	All
30'	Participants clinical case discussion (2x15')	Faculty
11:15-11:45	Coffee break	

11:45-13:45 120'	SESSION 2 Immuno-oncology treatment paradigms in advanced NSCLC	Chairs: Benjamin Besse, FR Anne-Marie Dingemans, NL
25'	State of the art for immunotherapy for non-AGA NSCLC	Lizza Hendriks, NL
5'	Q&A	All
25'	Focus on controversial subgroups for IO in non-AGA NSCLC	Solange Peters, CH
5'	Q&A	All
25'	Immunotherapy for AGA in NSCLC	Fabrice Barlesi, FR
5'	Q&A	All
30'	Participants clinical case discussion (2x15')	Faculty
13:45-14:45	Lunch	
14:45-16:25 100'	SESSION 3 Challenges and novel therapies in clinical oncology	Chairs: Solange Peters, CH Noemi Reguart, ES
20'	Standard second line treatments	Anne-Marie Dingemans, NL
5'	Q&A	All
25'	Antibody–drug conjugates	David Planchard, FR
5'	Q&A	All
25'	Bispecific antibodies and new treatment strategies	Benjamin Besse, FR
5'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
16:25-16:55	Coffee break	
16:55-18:55 120'	SESSION 4 Hitting the target in 2024	Chairs: Solange Peters, CH Jordi Remon, FR
25'	Sequence for biomarker testing in advanced NSCLC (IHC, PCR, NGS and more)	Keith M. Kerr, UK
5'	Q&A	All
25'	New treatment options for EGFR-mutant NSCLC	David Planchard, FR
5'	Q&A	All
25'	Therapeutic options in uncommon EGFR-mutant or HER2-mutant NSCLC	Anne-Marie Dingemans, NL
5'	Q&A	All
30'	Participants clinical case discussion (2x15')	Faculty
20:30	Dinner	

Saturday, 16 November 2024

09:00-10:45 105'	SESSION 5 Hitting even more targets in 2024	Chairs: Anne-Marie Dingemans, NL David Planchard, FR
25'	New and emerging targeted therapies in non-EGFR/HER2-mutant NSCLC	Jordi Remon, FR
5'	Q&A	All
25'	Gene fusion targets	Lizza Hendriks, NL
5'	Q&A	All
25'	ctDNA in the management of NSCLC patients	Keith M. Kerr, UK
5'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
10:45-11:15	Coffee break	
11:15-13:20 125'	SESSION 6 Treatment paradigms in rare situations	Chairs: Fabrice Barlesi, FR Lizza Hendriks, NL
25'	The evolving treatment landscape for mesothelioma	Solange Peters, CH
5'	Q&A	All
25'	Thymic malignancies: Current and future therapeutic options	Benjamin Besse, FR
5'	Q&A	All
30'	What's next in the management of SCLC?	Noemi Reguart, ES
5'	Q&A	All
30'	Participants clinical case discussion (2x15')	Faculty
13:20-13:30 10'	Conclusions and farewell	Solange Peters, CH David Planchard, FR
13:30-14:30	Lunch	

Note: Each 15 min slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / interactive panel discussion